Андрология и генитальная хирургия. 2023; 24: 36-47
Прогестерон и предстательная железа: история научного изучения и современный взгляд на проблему
https://doi.org/10.17650/2070-9781-2023-24-1-36-47Аннотация
С момента открытия и до недавнего времени научно-практический интерес к прогестерону существовал исключительно в рамках женской репродуктивной эндокринологии, акушерства и гинекологии. При этом потенциальная роль прогестерона в мужской эндокринной, репродуктивной и мочеполовой системах (с позиций исторически сложившейся трактовки данного полового стероидного гормона только лишь как женского стероида с преимущественно репродуктивными и антипролиферативными эффектами) долгие десятилетия оставалась в тени исследований. Однако в течение последних двух десятилетий стали накапливаться интересные данные о том, что прогестерон столь же важен для мужчин, как и для женщин. Более того, у обоих полов прогестерон выполняет не только «классические» (репродуктивные) функции, но и обладает широчайшим спектром так называемых неклассических (не репродуктивных) эффектов, позволяющих называть его своеобразным «серым кардиналом» стероидогенеза. В обзорной статье на основе данных доступной литературы рассматриваются общие и частные вопросы эндокринологии прогестерона в мужском организме. Более подробно освещены вопросы физиологической роли прогестерона в поддержании гормонально-метаболического статуса предстательной железы и механизмы его участия в патогенезе различных заболеваний предстательной железы.
Список литературы
1. Thornton J.W. Evolution of vertebrate steroid receptors from an ancestral estrogen receptor by ligand exploitation and serial genome expansions. Proc Natl Acad Sci U S A 2001;98(10):5671–6. DOI: 10.1073/pnas.091553298
2. McLachlan J.A. Environmental signalling: what embryos and evolution teach us about endocrine disrupting chemicals. Endocr Rev 2001;22(3):319–41. DOI: 10.1210/edrv.22.3.0432
3. Oettel M., Mukhopadhyay A.K. Progesterone: the forgotten hormone in men? Aging Male 2004;7(3):236–57. DOI: 10.1080/13685530400004199
4. Foresta C., Rossato M., Mioni R., Zorzi M. Progesterone induces capacitation in human spermatozoa. Andrologia 1992;24(1):33–5. DOI: 10.1111/j.1439-0272.1992.tb02605.x
5. Pietrobon E.O., Los Monclus M., Alberdi A.J., Fornés M.W. Progesterone receptor availability in mouse spermatozoa during epididymal transit and capacitation: ligand blot detection of progesterone-binding protein. J Androl 2003;24(4):612–20. DOI: 10.1002/j.1939-4640.2003.tb02713.x
6. Baranizadeh K., Mahboobian M.M., Amiri I. et al. Effects of progesterone nanoparticles on the sperm capacitation and acrosome reaction in asthenozoospermia men. Andrologia 2022;54(1):e14258. DOI: 10.1111/and.14258
7. Rasmusson A.M., Pineles S.L., Brown K.D., Pinna G. A role for deficits in GABAergic neurosteroids and their metabolites with NMDA receptor antagonist activity in the pathophysiology of posttraumatic stress disorder. J Neuroendocrinol 2022;34(2):e13062. DOI: 10.1111/jne.13062
8. Baker M.E., Katsu Y. Progesterone: an enigmatic ligand for the mineralocorticoid receptor. Biochem Pharmacol 2020;177:113976. DOI: 10.1016/j.bcp.2020.113976
9. Ohlsson C., Langenskiöld M., Smidfelt K. et al. Low progesterone and low estradiol levels associate with abdominal aortic aneurysms in men. J Clin Endocrinol Metab 2022;107(4):e1413–25. DOI: 10.1210/clinem/dgab867
10. Ghandehari S., Matusov Y., Pepkowitz S. et al. Progesterone in addition to standard of care vs standard of care alone in the treatment of men hospitalized with moderate to severe COVID-19: a randomized, controlled pilot trial. Chest 2021;160(1):74–84. DOI: 10.1016/j.chest.2021.02.024
11. Gadkar-Sable S., Shah C., Rosario G. et al. Progesterone receptors: various forms and functions in reproductive tissues. Front Biosci 2005;10:2118–30. DOI: 10.2741/1685.
12. Shackleton C., Malunowicz E. Apparent pregnene hydroxylation deficiency (APDH): seeking the parentage of an orphan metabolome. Steroids 2003;68(9):707–17. PMID: 14625002. DOI: 10.1016/s0039-128x(03)00115-6
13. Naville D., Keeney D.S., Jenkin G. et al. Regulation of expression of male-specific rat liver microsomal 3 beta-hydroxysteroid dehydrogenase. Mol Endocrinol 1991;5(8):1090–100. DOI: 10.1016/s0039- 10.1210/mend-5-8-1090
14. Zumoff B., Miller L., Levin J. et al. Follicular-phase serum progesterone levels of nonsmoking women do not differ from the levels of nonsmoking men. Steroids 1990;55(12):557–9. DOI: 10.1016/0039-128x(90)90052-d
15. Winkelmann B.R., März W., Boehm B.O. et al. Rationale and design of the LURIC study – a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. Pharmacogenomics 2001;2(Suppl 1):S1–73. DOI: 10.1517/14622416.2.1.S1
16. Arnett-Mansfield R.L., deFazo A., Wain G.V. et al. Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium. Cancer Res 2001;61(11):4576–82. PMID: 11389093.
17. Lieberman A., Curtis L. In defense of progesterone: a review of the literature. Altern Ther Health Med 2017; 23(6):24–32. PMID: 29055286.
18. Samadi A., Carlson C.G., Gueorguiev A., Cenedella R.J. Rapid, non-genomic actions of progesterone and estradiol on steady-state calcium and resting calcium influx in lens epithelial cells. Pflugers Arch 2002;444(6):700–9. DOI: 10.1007/s00424-002-0889-7
19. Pedersen S.B., Kristensen K., Richelsen B. Anti-glucocorticoid effects of progesterone in vivo on rat adipose tissue metabolism. Steroids 2003;68(6):543–50. DOI: 10.1016/s0039-128х(03)00084-9
20. Falkenstein E., Tillmann H.-C., Christ M. et al. Multiple actions of steroid hormones – a focus on rapid, nongenomic effects. Pharmacol Rev 2000;52(4):513–55. PMID: 11121509.
21. Rajaram R.D., Brisken C. Paracrine signaling by progesterone. Mol Cell Endocrinol 2012;357(1–2):80–90. DOI: 10.1016/j.mce.2011.09.018
22. Sciarra A., Innocenzi M., Ravaziol M. et al. [Role of neuroendocrine cells in prostate cancer progression (In Italian)]. Urologia 2011;78(2):126–31. DOI: 10.5301/RU.2011.8337
23. Hermann M., Untergasser G., Rumpold H., Berger P. Aging of the male reproductive system. Exp Gerontol 2000;35(9–10): 1267–79. DOI: 10.1016/s0531-5565(00)00159-5
24. Song L., Shen W., Zhang H. et al. Differential expression of androgen, estrogen, and progesterone receptors in benign prostatic hyperplasia. Bosn J Basic Med Sci 2016;16(3):201–8. DOI: 10.17305/bjbms.2016.1209
25. Chen R., Yu Y., Dong X. Progesterone receptor in the prostate: a potential suppressor for benign prostatic hyperplasia and prostate cancer. J Steroid Biochem Mol Biol 2017;166:91–6. DOI: 10.1016/j.jsbmb.2016.04.008
26. Kaore S.N., Langade D.K., Yadav V.K. et al. Novel actions of progesterone: what we know today and what will be the scenario in the future? J Pharm Pharmacol 2012;64(8):1040–62. DOI: 10.1111/j.2042-7158.2012.01464.х
27. Da Silva M.H.A., De Souza D.B. Current evidence for the involvement of sex steroid receptors and sex hormones in benign prostatic hyperplasia. Res Rep Urol 2019;11:1–8. DOI: 10.2147/RRU.S155609.
28. Fochi R.A., Santos F.C., Goes R.M., Taboga S.R. Progesterone as a morphological regulatory factor of the male and female gerbil prostate. Int J Exp Pathol 2013;94(6):373–86. DOI: 10.1111/iep.12050
29. Yu Y., Yang O., Fazli L. et al. Progesterone receptor expression during prostate cancer progression suggests a role of this receptor in stromal cell differentiation. Prostate 2015;75(10):1043–50. DOI: 10.1002/pros.22988
30. Grindstad T., Andersen S., Al-Saad S. et al. High progesterone receptor expression in prostate cancer is associated with clinical failure. PLoS One 2015;10(2):e0116691. DOI: 10.1371/journal.pone.0116691
31. Grindstad T., Richardsen E., Andersen S. et al. Progesterone receptors in prostate cancer: progesterone receptor B is the isoform associated with disease progression. Sci Rep 2018;8(1):11358. DOI: 10.1038/s41598-018-29520-5
32. Spirina L.V., Kovaleva I.V., Usynin E.A. et al. Progesterone receptor expression in the benign prostatic hyperplasia and prostate cancer tissues, relation with transcription, growth factors, hormone reception and components of the AKT/mTOR signaling pathway. Asian Pac J Cancer Prev 2020;21(2):423–9. DOI: 10.31557/APJCP.2020.21.2.423
33. Bera K.N., Yadav S.K., Prakash O. et al. Immunoexpression of estrogen receptor-β and progesterone receptor in prostate adenocarcinoma, does it inhibit neoplastic proliferation and invasion? Indian J Pathol Microbiol 2020; 63(Supplement): S30–S33. DOI: 10.4103/IJPM.IJPM_467_18
34. Li W., Klein R.J. Genome-wide association study identifies a role for the progesterone receptor in benign prostatic hyperplasia risk. Prostate Cancer Prostatic Dis 2021;24(2):492–8. DOI: 10.1038/s41391-020-00303-2
35. Yang M., Li J.C., Tao C. et al. PAQR6 upregulation is associated with AR signaling and unfavorite prognosis in prostate cancers. Biomolecules 2021;11(9):1383. DOI: 10.3390/biom11091383
36. Tao C., Liu W., Yan X. et al. PAQR5 expression is suppressed by TGFβ1 and associated with a poor survival outcome in renal clear cell carcinoma. Front Oncol 2022;11:827344. DOI: 10.3389/fonc.2021.827344
37. Check J.H. The role of progesterone and the progesterone receptor in cancer. Expert Rev Endocrinol Metab 2017;12(3):187–97. DOI: 10.1080/17446651.2017.1314783
38. Pitchford A.G. Gestronol hexanoate (SH582) and benign prostatic hypertrophy. Proc R Soc Med 1972;65(2):128–9. PMID: 4117436.
39. Ibba A.L. [On the treatment of prostatic adenoma with hydroxyprogesterone caronate (In Italian)]. Osp Ital Chir 1968;19(4):427–42. PMID: 4180617.
40. Musierowicz A. [Hormonal treatment of prostatic hypertrophy with special reference to the usefulness of gestagens (In Polish)]. Wiad Lek 1974;27(22):1985–8. PMID: 4140619.
41. Щербаков А.П. Применение прогестерона при аденоме предстательной железы. Урология и нефрология 1978;1:72–6.
42. Nagel R., Hargenda B. [Treatment of benign prostatic hypertrophy with progestogens including gestonorone caproate. (In Japanese)]. Hinyokika Kiyo 1970;16(9):423–8. PMID: 4097356.
43. Momose S., Hidaka M., Oota Y., Oomaru K. [The clinical effects of SH 582 (gestonorone caproate) on benign prostatic hypertrophy (In Japanese)]. Hinyokika Kiyo 1970;16(9):551–4. PMID: 4097366.
44. Tanaka H., Fukushige M., Shiraishi T. [Treatment of prostatic hypertrophy with progestational steroid (gestonorone caproate) (In Japanese)]. Hinyokika Kiyo 1970;16(9):531–50. PMID: 4097365.
45. Meiraz D., Margolin Y., Lev-Ran A., Lazebnik J. Treatment of benign prostatic hyperplasia with hydroxyprogesterone-caproate: placebo-controlled study. Urology 1977;9(2):144–8. DOI: 10.1016/0090-4295(77)90184-4
46. Schacter L., Rozencweig M., Canetta R. et al. Megestrol acetate: clinical experience. Cancer Treat Rev 1989;16(1):49–63. DOI: 10.1016/0305-7372(89)90004-2
47. Карпушин В.Т., Сапожников В.В. Фонофорез гидроксипрогестерона капроната в лечении больных с аденомой предстательной железы, осложненной дизурией. Вопросы курортологии и физиотерапии. 1981;6:46–9. PMID: 6175097.
48. Григорьева В.Д., Сапожников В.В., Пономарев Ю.Т. и др. Применение ректального фонофореза гидроксипрогестерона капроната для коррекции эндокринных нарушений у пациентов с аденомой простаты. Вопросы курортологии и физиотерапии 1984;6:29–32. PMID: 6084361.
49. Onu P.E. Depot medroxyprogesterone in the management of benign prostatic hyperplasia. Eur Urol 1995;28(3):229–35. DOI: 10.1159/000475056
50. Albouy M., Sanquer A., Maynard L., Eun H.M. Efficacies of osaterone and delmadinone in the treatment of benign prostatichyperplasia in dogs. Vet Rec 2008;163(6):179–83. DOI: 10.1136/vr.163.6.179
51. Fujimoto K., Hirao Y., Ohashi Y. et al. The effects of chlormadinone acetate on lower urinary tract symptoms and erectile functions of patients with benign prostatic hyperplasia: a prospective multicenter clinical study. Adv Urol 2013;2013:584678. DOI: 10.1155/2013/584678
52. Li W., Li X., Zhang B. et al. Current progresses and trends in the development of progesterone receptor modulators. Curr Med Chem 2016;23(23):2507–54. DOI: 10.2174/0929867323666160428105310
53. Bouchard P. Selective progesterone receptor modulators: a class with multiple actions and applications in reproductive endocrinology, and gynecology. Gynecol Endocrinol 2014;30(10):683–4. DOI: 10.3109/09513590.2014.950647
Andrology and Genital Surgery. 2023; 24: 36-47
Progesterone and prostate: a history of scientific study and the modern view of the problem
https://doi.org/10.17650/2070-9781-2023-24-1-36-47Abstract
From the moment of discovery until recently, scientific and practical interest in progesterone has been focused exclusively on female reproductive endocrinology and obstetrics and gynecology. At the same time, the potential role of progesterone in the male endocrine, reproductive and genitourinary systems from the standpoint of the historically established interpretation of this sex steroid hormone only as a female steroid with predominantly reproductive and antiproliferative effects has remained in the shadow of research for many decades. However, over the past two decades, interesting data has begun to accumulate that progesterone is just as important for men as for women. Moreover, in both sexes progesterone performs not only classical (reproductive) effects, but also has a wide range of so-called non-classical (non-productive) effects, which make it possible to call it a kind of “gray cardinal” of steroidogenesis. In the review article, based on the available literature, general and particular issues of endocrinology of progesterone in the male body are considered. The questions of the physiological role of progesterone in maintaining the hormonal and metabolic status of the prostate gland and the mechanisms of its participation in the pathogenesis of various prostate diseases are covered in more detail.
References
1. Thornton J.W. Evolution of vertebrate steroid receptors from an ancestral estrogen receptor by ligand exploitation and serial genome expansions. Proc Natl Acad Sci U S A 2001;98(10):5671–6. DOI: 10.1073/pnas.091553298
2. McLachlan J.A. Environmental signalling: what embryos and evolution teach us about endocrine disrupting chemicals. Endocr Rev 2001;22(3):319–41. DOI: 10.1210/edrv.22.3.0432
3. Oettel M., Mukhopadhyay A.K. Progesterone: the forgotten hormone in men? Aging Male 2004;7(3):236–57. DOI: 10.1080/13685530400004199
4. Foresta C., Rossato M., Mioni R., Zorzi M. Progesterone induces capacitation in human spermatozoa. Andrologia 1992;24(1):33–5. DOI: 10.1111/j.1439-0272.1992.tb02605.x
5. Pietrobon E.O., Los Monclus M., Alberdi A.J., Fornés M.W. Progesterone receptor availability in mouse spermatozoa during epididymal transit and capacitation: ligand blot detection of progesterone-binding protein. J Androl 2003;24(4):612–20. DOI: 10.1002/j.1939-4640.2003.tb02713.x
6. Baranizadeh K., Mahboobian M.M., Amiri I. et al. Effects of progesterone nanoparticles on the sperm capacitation and acrosome reaction in asthenozoospermia men. Andrologia 2022;54(1):e14258. DOI: 10.1111/and.14258
7. Rasmusson A.M., Pineles S.L., Brown K.D., Pinna G. A role for deficits in GABAergic neurosteroids and their metabolites with NMDA receptor antagonist activity in the pathophysiology of posttraumatic stress disorder. J Neuroendocrinol 2022;34(2):e13062. DOI: 10.1111/jne.13062
8. Baker M.E., Katsu Y. Progesterone: an enigmatic ligand for the mineralocorticoid receptor. Biochem Pharmacol 2020;177:113976. DOI: 10.1016/j.bcp.2020.113976
9. Ohlsson C., Langenskiöld M., Smidfelt K. et al. Low progesterone and low estradiol levels associate with abdominal aortic aneurysms in men. J Clin Endocrinol Metab 2022;107(4):e1413–25. DOI: 10.1210/clinem/dgab867
10. Ghandehari S., Matusov Y., Pepkowitz S. et al. Progesterone in addition to standard of care vs standard of care alone in the treatment of men hospitalized with moderate to severe COVID-19: a randomized, controlled pilot trial. Chest 2021;160(1):74–84. DOI: 10.1016/j.chest.2021.02.024
11. Gadkar-Sable S., Shah C., Rosario G. et al. Progesterone receptors: various forms and functions in reproductive tissues. Front Biosci 2005;10:2118–30. DOI: 10.2741/1685.
12. Shackleton C., Malunowicz E. Apparent pregnene hydroxylation deficiency (APDH): seeking the parentage of an orphan metabolome. Steroids 2003;68(9):707–17. PMID: 14625002. DOI: 10.1016/s0039-128x(03)00115-6
13. Naville D., Keeney D.S., Jenkin G. et al. Regulation of expression of male-specific rat liver microsomal 3 beta-hydroxysteroid dehydrogenase. Mol Endocrinol 1991;5(8):1090–100. DOI: 10.1016/s0039- 10.1210/mend-5-8-1090
14. Zumoff B., Miller L., Levin J. et al. Follicular-phase serum progesterone levels of nonsmoking women do not differ from the levels of nonsmoking men. Steroids 1990;55(12):557–9. DOI: 10.1016/0039-128x(90)90052-d
15. Winkelmann B.R., März W., Boehm B.O. et al. Rationale and design of the LURIC study – a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. Pharmacogenomics 2001;2(Suppl 1):S1–73. DOI: 10.1517/14622416.2.1.S1
16. Arnett-Mansfield R.L., deFazo A., Wain G.V. et al. Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium. Cancer Res 2001;61(11):4576–82. PMID: 11389093.
17. Lieberman A., Curtis L. In defense of progesterone: a review of the literature. Altern Ther Health Med 2017; 23(6):24–32. PMID: 29055286.
18. Samadi A., Carlson C.G., Gueorguiev A., Cenedella R.J. Rapid, non-genomic actions of progesterone and estradiol on steady-state calcium and resting calcium influx in lens epithelial cells. Pflugers Arch 2002;444(6):700–9. DOI: 10.1007/s00424-002-0889-7
19. Pedersen S.B., Kristensen K., Richelsen B. Anti-glucocorticoid effects of progesterone in vivo on rat adipose tissue metabolism. Steroids 2003;68(6):543–50. DOI: 10.1016/s0039-128kh(03)00084-9
20. Falkenstein E., Tillmann H.-C., Christ M. et al. Multiple actions of steroid hormones – a focus on rapid, nongenomic effects. Pharmacol Rev 2000;52(4):513–55. PMID: 11121509.
21. Rajaram R.D., Brisken C. Paracrine signaling by progesterone. Mol Cell Endocrinol 2012;357(1–2):80–90. DOI: 10.1016/j.mce.2011.09.018
22. Sciarra A., Innocenzi M., Ravaziol M. et al. [Role of neuroendocrine cells in prostate cancer progression (In Italian)]. Urologia 2011;78(2):126–31. DOI: 10.5301/RU.2011.8337
23. Hermann M., Untergasser G., Rumpold H., Berger P. Aging of the male reproductive system. Exp Gerontol 2000;35(9–10): 1267–79. DOI: 10.1016/s0531-5565(00)00159-5
24. Song L., Shen W., Zhang H. et al. Differential expression of androgen, estrogen, and progesterone receptors in benign prostatic hyperplasia. Bosn J Basic Med Sci 2016;16(3):201–8. DOI: 10.17305/bjbms.2016.1209
25. Chen R., Yu Y., Dong X. Progesterone receptor in the prostate: a potential suppressor for benign prostatic hyperplasia and prostate cancer. J Steroid Biochem Mol Biol 2017;166:91–6. DOI: 10.1016/j.jsbmb.2016.04.008
26. Kaore S.N., Langade D.K., Yadav V.K. et al. Novel actions of progesterone: what we know today and what will be the scenario in the future? J Pharm Pharmacol 2012;64(8):1040–62. DOI: 10.1111/j.2042-7158.2012.01464.kh
27. Da Silva M.H.A., De Souza D.B. Current evidence for the involvement of sex steroid receptors and sex hormones in benign prostatic hyperplasia. Res Rep Urol 2019;11:1–8. DOI: 10.2147/RRU.S155609.
28. Fochi R.A., Santos F.C., Goes R.M., Taboga S.R. Progesterone as a morphological regulatory factor of the male and female gerbil prostate. Int J Exp Pathol 2013;94(6):373–86. DOI: 10.1111/iep.12050
29. Yu Y., Yang O., Fazli L. et al. Progesterone receptor expression during prostate cancer progression suggests a role of this receptor in stromal cell differentiation. Prostate 2015;75(10):1043–50. DOI: 10.1002/pros.22988
30. Grindstad T., Andersen S., Al-Saad S. et al. High progesterone receptor expression in prostate cancer is associated with clinical failure. PLoS One 2015;10(2):e0116691. DOI: 10.1371/journal.pone.0116691
31. Grindstad T., Richardsen E., Andersen S. et al. Progesterone receptors in prostate cancer: progesterone receptor B is the isoform associated with disease progression. Sci Rep 2018;8(1):11358. DOI: 10.1038/s41598-018-29520-5
32. Spirina L.V., Kovaleva I.V., Usynin E.A. et al. Progesterone receptor expression in the benign prostatic hyperplasia and prostate cancer tissues, relation with transcription, growth factors, hormone reception and components of the AKT/mTOR signaling pathway. Asian Pac J Cancer Prev 2020;21(2):423–9. DOI: 10.31557/APJCP.2020.21.2.423
33. Bera K.N., Yadav S.K., Prakash O. et al. Immunoexpression of estrogen receptor-β and progesterone receptor in prostate adenocarcinoma, does it inhibit neoplastic proliferation and invasion? Indian J Pathol Microbiol 2020; 63(Supplement): S30–S33. DOI: 10.4103/IJPM.IJPM_467_18
34. Li W., Klein R.J. Genome-wide association study identifies a role for the progesterone receptor in benign prostatic hyperplasia risk. Prostate Cancer Prostatic Dis 2021;24(2):492–8. DOI: 10.1038/s41391-020-00303-2
35. Yang M., Li J.C., Tao C. et al. PAQR6 upregulation is associated with AR signaling and unfavorite prognosis in prostate cancers. Biomolecules 2021;11(9):1383. DOI: 10.3390/biom11091383
36. Tao C., Liu W., Yan X. et al. PAQR5 expression is suppressed by TGFβ1 and associated with a poor survival outcome in renal clear cell carcinoma. Front Oncol 2022;11:827344. DOI: 10.3389/fonc.2021.827344
37. Check J.H. The role of progesterone and the progesterone receptor in cancer. Expert Rev Endocrinol Metab 2017;12(3):187–97. DOI: 10.1080/17446651.2017.1314783
38. Pitchford A.G. Gestronol hexanoate (SH582) and benign prostatic hypertrophy. Proc R Soc Med 1972;65(2):128–9. PMID: 4117436.
39. Ibba A.L. [On the treatment of prostatic adenoma with hydroxyprogesterone caronate (In Italian)]. Osp Ital Chir 1968;19(4):427–42. PMID: 4180617.
40. Musierowicz A. [Hormonal treatment of prostatic hypertrophy with special reference to the usefulness of gestagens (In Polish)]. Wiad Lek 1974;27(22):1985–8. PMID: 4140619.
41. Shcherbakov A.P. Primenenie progesterona pri adenome predstatel'noi zhelezy. Urologiya i nefrologiya 1978;1:72–6.
42. Nagel R., Hargenda B. [Treatment of benign prostatic hypertrophy with progestogens including gestonorone caproate. (In Japanese)]. Hinyokika Kiyo 1970;16(9):423–8. PMID: 4097356.
43. Momose S., Hidaka M., Oota Y., Oomaru K. [The clinical effects of SH 582 (gestonorone caproate) on benign prostatic hypertrophy (In Japanese)]. Hinyokika Kiyo 1970;16(9):551–4. PMID: 4097366.
44. Tanaka H., Fukushige M., Shiraishi T. [Treatment of prostatic hypertrophy with progestational steroid (gestonorone caproate) (In Japanese)]. Hinyokika Kiyo 1970;16(9):531–50. PMID: 4097365.
45. Meiraz D., Margolin Y., Lev-Ran A., Lazebnik J. Treatment of benign prostatic hyperplasia with hydroxyprogesterone-caproate: placebo-controlled study. Urology 1977;9(2):144–8. DOI: 10.1016/0090-4295(77)90184-4
46. Schacter L., Rozencweig M., Canetta R. et al. Megestrol acetate: clinical experience. Cancer Treat Rev 1989;16(1):49–63. DOI: 10.1016/0305-7372(89)90004-2
47. Karpushin V.T., Sapozhnikov V.V. Fonoforez gidroksiprogesterona kapronata v lechenii bol'nykh s adenomoi predstatel'noi zhelezy, oslozhnennoi dizuriei. Voprosy kurortologii i fizioterapii. 1981;6:46–9. PMID: 6175097.
48. Grigor'eva V.D., Sapozhnikov V.V., Ponomarev Yu.T. i dr. Primenenie rektal'nogo fonoforeza gidroksiprogesterona kapronata dlya korrektsii endokrinnykh narushenii u patsientov s adenomoi prostaty. Voprosy kurortologii i fizioterapii 1984;6:29–32. PMID: 6084361.
49. Onu P.E. Depot medroxyprogesterone in the management of benign prostatic hyperplasia. Eur Urol 1995;28(3):229–35. DOI: 10.1159/000475056
50. Albouy M., Sanquer A., Maynard L., Eun H.M. Efficacies of osaterone and delmadinone in the treatment of benign prostatichyperplasia in dogs. Vet Rec 2008;163(6):179–83. DOI: 10.1136/vr.163.6.179
51. Fujimoto K., Hirao Y., Ohashi Y. et al. The effects of chlormadinone acetate on lower urinary tract symptoms and erectile functions of patients with benign prostatic hyperplasia: a prospective multicenter clinical study. Adv Urol 2013;2013:584678. DOI: 10.1155/2013/584678
52. Li W., Li X., Zhang B. et al. Current progresses and trends in the development of progesterone receptor modulators. Curr Med Chem 2016;23(23):2507–54. DOI: 10.2174/0929867323666160428105310
53. Bouchard P. Selective progesterone receptor modulators: a class with multiple actions and applications in reproductive endocrinology, and gynecology. Gynecol Endocrinol 2014;30(10):683–4. DOI: 10.3109/09513590.2014.950647
